Back to Directory
Idursulfase
Performance & EnduranceEnzyme replacement for MPS II (Hunter syndrome).
Key Benefits
- ✓Treats MPS II
- ✓Enzyme replacement
- ✓Improves respiratory function
- ✓Reduces organomegaly
- ✓Improves endurance
Dosing Information
Dosage Range
0.5 mg/kg
Frequency
Once weekly IV
Typical Duration
Lifelong
Detailed Protocol
Administered via intravenous infusion weekly. Hospital or infusion center. Premedication recommended. Lifelong therapy for MPS II patients.
About Idursulfase
Idursulfase (Elaprase) is recombinant human iduronate-2-sulfatase for MPS II (Hunter syndrome). Enzyme replacement therapy for this rare X-linked lysosomal storage disorder. FDA-approved.
Research Notes
FDA-approved in 2006 for MPS II. Standard treatment for Hunter syndrome. Improves somatic manifestations but limited CNS penetration. Lifelong therapy.
Potential Side Effects
- •Infusion reactions
- •Antibody development
- •Headache
- •Fever
- •Requires monitoring
Always consult with a healthcare professional before starting any peptide therapy.